Immune-checkpoint targeting drug conjugates: a novel class of promising therapeutic agents for cancer treatment.

NPJ Precis Oncol · 2025 · PMC12223136 · PMID 40603576

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

B7-H3 expression levels did not correlate with objective tumor response; however, patients with high B7-H3 immunohistochemistry (IHC) expression ( ≥ 1%) showed a trend towards a longer mPFS 23 .

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.